TANZEUM
Biological
GlaxoSmithKline, LLC.
Total Payments
$19.4M
Transactions
1,623
Doctors
51
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2018 | $40.68 | 5 | 5 |
| 2017 | $19.4M | 1,618 | 46 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $19.4M | 1,529 | 99.8% |
| Consulting Fee | $30,588 | 20 | 0.2% |
| Travel and Lodging | $1,483 | 10 | 0.0% |
| Food and Beverage | $1,046 | 64 | 0.0% |
Payments by Type
Research
$19.4M
1,529 transactions
General
$33,117
94 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| A long term, randomised, double blind, placebo controlled study to determine the effect of albiglutide, when added to standard blood glucose lowering therapies, on major cardiovascular events in patients with Type 2 diabetes mellitus | GlaxoSmithKline, LLC. | $15.4M | 5 |
| A Repeat dose Study in Subjects with Type 2 Diabetes Mellitus to Assess the Efficacy, Safety, Tolerability and Pharmacodynamics, of Albiglutide Liquid Drug Product | GlaxoSmithKline, LLC. | $2.8M | 0 |
| Study 200977 Albiglutide Insulin Glargine versus Insulin Lispro Insulin Glargine in the Treatment of Subjects with Type 2 Diabetes Mellitus The Switch Study | GlaxoSmithKline, LLC. | $590,765 | 0 |
| A Randomized Double blind Single dose Crossover Study to Compare Two Albiglutide Drug Products for Bioequivalence in Healthy Adult Subjects | GlaxoSmithKline, LLC. | $262,799 | 0 |
| An Open label Extension to Study 200952 to Evaluate the Longterm Safety, Tolerability and Pharmacodynamics of Albiglutide Liquid Drug Product in Subjects with Type 2 Diabetes Mellitus | GlaxoSmithKline, LLC. | $108,365 | 0 |
| Study 201840 An Exploratory Randomized, 2 Part, Single blind, 2 Period Crossover Study Comparing the Effect of Albiglutide with Exenatide on Regional Brain Activity Related to Nausea in Healthy Volunteers | GlaxoSmithKline, LLC. | $103,357 | 0 |
| A Randomized, Open label, Active Controlled, Parallel Group, Exploratory Study on the Effects of Repeated Doses of Albiglutide compared to Exenatide on Gastric Myoelectrical Activity and Gastric Emptying in Subjects with Type 2 Diabetes Mellitus | GlaxoSmithKline, LLC. | $46,592 | 0 |
| A randomized, double blind, placebo controlled, multi center study to evaluate the pharmacokinetics, safety and efficacy of albiglutide for the treatment of type 2 diabetes mellitus in pediatric patients | GlaxoSmithKline, LLC. | $11,500 | 0 |
| Study 111892 Albiglutide Versus Placebo as Add on to Intensified Basal Bolus Insulin Therapy in Subjects With Type 2 Diabetes Mellitus | GlaxoSmithKline, LLC. | $8,500 | 0 |
| A randomized, double blind, single dose, placebo controlled, 2 way cross over study evaluating effect of albiglutide on cholecystokinin induced gallbladder emptying in fasting healthy subjects | GlaxoSmithKline, LLC. | $5,894 | 0 |
Top Doctors Receiving Payments for TANZEUM
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Durham, NC | $19.3M | 1,453 |
| , M.D | Cardiovascular Disease | Durham, NC | $24,444 | 20 |
| , MD | Endocrinology, Diabetes & Metabolism | Durham, NC | $19,139 | 42 |
| , M.D | Cardiovascular Disease | Durham, NC | $16,315 | 20 |
| , MD | Internal Medicine | Washington, DC | $14,800 | 11 |
| , MD | Cardiovascular Disease | Kansas City, MO | $12,907 | 9 |
| , MD | Endocrinology, Diabetes & Metabolism | Columbus, OH | $10,043 | 12 |
| , MD | Cardiovascular Disease | Dallas, TX | $3,478 | 8 |
| , M.D | Cardiovascular Disease | Brookline, MA | $2,240 | 1 |
| James Perez | Internal Medicine | Elizabeth, NJ | $27.16 | 1 |
| , RETIRED, MD | Family Medicine | Charleston, WV | $25.63 | 2 |
| , MD, RETIRED | Family Medicine | Charleston, WV | $25.63 | 2 |
| , MD | Emergency Medicine | Charleston, WV | $25.63 | 2 |
| , MD | Emergency Medicine | Charleston, WV | $25.63 | 2 |
| , MD | Internal Medicine | Dyersburg, TN | $19.94 | 1 |
| , D.O | Internal Medicine | Charleston, WV | $19.91 | 1 |
| , MD | Family Medicine | Ironton, OH | $17.46 | 1 |
| , MD | Family Medicine | Ironton, OH | $17.46 | 1 |
| , M.D | Family Medicine | Gallipolis, OH | $17.44 | 1 |
| , M.D | Critical Care Medicine | Palatka, FL | $17.08 | 1 |
| , DO | Family Medicine | Sutton, WV | $17.04 | 1 |
| , MD | Pediatrics | Rutherfordton, NC | $16.99 | 1 |
| , M.D | Internal Medicine | Staten Island, NY | $15.86 | 1 |
| , M.D | Internal Medicine | Staten Island, NY | $15.86 | 1 |
| , M.D | Internal Medicine | Staten Island, NY | $15.86 | 1 |
Ad
Manufacturing Companies
- GlaxoSmithKline, LLC. $19.4M
Product Information
- Type Biological
- Total Payments $19.4M
- Total Doctors 51
- Transactions 1,623
About TANZEUM
TANZEUM is a biological associated with $19.4M in payments to 51 healthcare providers, recorded across 1,623 transactions in the CMS Open Payments database. The primary manufacturer is GlaxoSmithKline, LLC..
Payment data is available from 2017 to 2018. In 2018, $40.68 was paid across 5 transactions to 5 doctors.
The most common payment nature for TANZEUM is "Unspecified" ($19.4M, 99.8% of total).
TANZEUM is associated with 10 research studies, including "A long term, randomised, double blind, placebo controlled study to determine the effect of albiglutide, when added to standard blood glucose lowering therapies, on major cardiovascular events in patients with Type 2 diabetes mellitus" ($15.4M).